SCOPUS 정보 검색 플랫폼

Volumn 12, Issue SUPPL. 1, 2005, Pages

Growth factor signalling in clinical breast cancer and its impact on response to conventional therapies: The Edinburgh experience

(6) Miller, W R a Anderson, T J a White, S a Evans, D b Krause, A b Dixon, J M a

a WESTERN GENERAL HOSPITAL (United Kingdom)

b NOVARTIS PHARMA AG (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ESTROGEN RECEPTOR; EXEMESTANE; FORMESTANE; GONADORELIN AGONIST; KI 67 ANTIGEN; LETROZOLE; PROGESTERONE; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADJUVANT THERAPY; BREAST CANCER; CELL PROLIFERATION; CONFERENCE PAPER; DRUG RESPONSE; HORMONAL THERAPY; HUMAN; SIGNAL TRANSDUCTION; THERAPY RESISTANCE; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; FEMALE; HUMANS; NEOADJUVANT THERAPY; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION;

EID: 25844433766 PISSN: 13510088 EISSN: None Source Type: Journal
DOI: 10.1677/erc.1.00995 Document Type: Conference Paper

Times cited : (8)

References (5)

1
- 0035884620
- Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial
- Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Janicke F, Miller WR, Evans DB, Dugan M & Brady C 2001 Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. Journal of Clinical Oncology 19 3808-3816.
- (2001) Journal of Clinical Oncology , vol.19 , pp. 3808-3816
- Ellis, M.J.¹ Coop, A.² Singh, B.³ Mauriac, L.⁴ Llombert-Cussac, A.⁵ Janicke, F.⁶ Miller, W.R.⁷ Evans, D.B.⁸ Dugan, M.⁹ Brady, C.¹⁰

2
- 0022979888
- A human tumour model
- Forrest AP, Levack PA, Chetty U, Hawkins RA, Miller WR, Smyth JF & Anderson TJ 1986 A human tumour model. Lancet 2 840-842.
- (1986) Lancet , vol.2 , pp. 840-842
- Forrest, A.P.¹ Levack, P.A.² Chetty, U.³ Hawkins, R.A.⁴ Miller, W.R.⁵ Smyth, J.F.⁶ Anderson, T.J.⁷

3
- 0030914830
- Expression of Ki-S1 and BCL-2 and the response to primary tamoxifen therapy in elderly patients with breast cancer
- Keen JC, Dixon JM, Miller EP, Cameron DA, Chetty U, Hanby A, Bellamy C & Miller WR 1997 Expression of Ki-S1 and BCL-2 and the response to primary tamoxifen therapy in elderly patients with breast cancer. Breast Cancer Research and Treatment 44 123-134.
- (1997) Breast Cancer Research and Treatment , vol.44 , pp. 123-134
- Keen, J.C.¹ Dixon, J.M.² Miller, E.P.³ Cameron, D.A.⁴ Chetty, U.⁵ Hanby, A.⁶ Bellamy, C.⁷ Miller, W.R.⁸

4
- 0001902073
- Neoadjuvant endocrine treatment: The Edinburgh experience
- Eds M Doswett & A Howell. Amsterdam: Elsevier
- Miller WR, Anderson TJ, Hawkins RA, Keen J & Dixon JM 1999 Neoadjuvant endocrine treatment: the Edinburgh experience. In Primary Medical Therapy for Breast Cancer: Clinical and Biological Aspects, pp 89-99. Eds M Doswett & A Howell. Amsterdam: Elsevier.
- (1999) Primary Medical Therapy for Breast Cancer: Clinical and Biological Aspects , pp. 89-99
- Miller, W.R.¹ Anderson, T.J.² Hawkins, R.A.³ Keen, J.⁴ Dixon, J.M.⁵

5
- 25844451143
- Aromatase 2004, Edinburgh, UK, 6-8 September 2004
- Miller WR & Larionov A 2005 Aromatase 2004, Edinburgh, UK, 6-8 September 2004. Breast Cancer Research 7 E2.
- (2005) Breast Cancer Research , vol.7
- Miller, W.R.¹ Larionov, A.²

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.